DBV Technologies S.A. (DBVT) At $21.43 Forms Bottom; 3 Analysts Covering Infinity Pharmaceuticals, Inc. (INFI)

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Logo

Among 10 analysts covering Infinity Pharmaceutical (NASDAQ:INFI), 3 have Buy rating, 0 Sell and 7 Hold. Therefore 30% are positive. Infinity Pharmaceutical had 17 analyst reports since August 7, 2015 according to SRatingsIntel. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The stock has “Neutral” rating by on Tuesday, June 14. The firm earned “Market Perform” rating on Tuesday, June 14 by JMP Securities. The company was upgraded on Monday, September 21 by Morgan Stanley. The stock has “Underperform” rating by Wedbush on Tuesday, March 22. William Blair downgraded Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) on Wednesday, June 15 to “Market Perform” rating. As per Thursday, May 31, the company rating was initiated by Seaport Global. The stock of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has “Neutral” rating given on Thursday, February 25 by Wedbush. As per Wednesday, March 2, the company rating was initiated by FBR Capital. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, June 15. See Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) latest ratings:

31/05/2018 Broker: Seaport Global Rating: Buy New Target: $4.0000 Initiate

DBV Technologies S.A. (DBVT) formed multiple bottom with $20.79 target or 3.00% below today’s $21.43 share price. DBV Technologies S.A. (DBVT) has $1.27 billion valuation. The stock increased 0.23% or $0.05 during the last trading session, reaching $21.43. About 67,685 shares traded. DBV Technologies S.A. (NASDAQ:DBVT) has declined 29.21% since June 12, 2017 and is downtrending. It has underperformed by 41.78% the S&P500. Some Historical DBVT News: ; 08/05/2018 – DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting; 29/05/2018 – DBV TECHNOLOGIES SA DBV.PA – VIASKIN PEANUT: AFTER THREE YEARS OF TREATMENT, RISK REDUCTION IN DEVELOPING AN ALLERGIC REACTION INCREASED TO MORE THAN 99%; 20/03/2018 – DBV TECHNOLOGIES: DBV TECHNOLOGIES: LAUNCH OF A PROPOSED GLOBAL; 14/03/2018 – DBV TECHNOLOGIES REPORTS FULL YEAR 2017 FINANCIAL RESULTS; 16/05/2018 – DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors; 16/03/2018 – REG-DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F; 13/04/2018 – Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automatio; 20/03/2018 – DBV TECHNOLOGIES SA – PLANS TO USE NET PROCEEDS FROM GLOBAL OFFERING TO FUND DEVELOPMENT AND COMMERCIALIZATION OF VIASKIN PEANUT, OTHERS; 08/05/2018 – REG-DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting; 16/03/2018 – DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $103.73 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Since March 5, 2018, it had 1 buy, and 1 sale for $2.96 million activity. Another trade for 5,000 shares valued at $13,890 was sold by Perkins Adelene Q. 1.51M Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) shares with value of $2.97M were bought by BVF PARTNERS L P/IL.

The stock decreased 1.60% or $0.03 during the last trading session, reaching $1.85. About 413,639 shares traded. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) has risen 16.67% since June 12, 2017 and is uptrending. It has outperformed by 4.10% the S&P500. Some Historical INFI News: ; 09/04/2018 – Merck: Keytruda Monotherapy Meets Primary Endpoint in Phase 3 Study; 26/03/2018 – BRISTOL-MYERS SQUIBB CO – CHMP RECOMMENDATION OF OPDIVO WILL NOW BE REVIEWED BY EUROPEAN COMMISSION; 08/05/2018 – Infinity Announces Presentations On IPI-549 At Upcoming American Society of Clinical Oncology Annual Meeting; 08/05/2018 – INFINITY PHARMA 1Q LOSS/SHR 18C, EST. LOSS/SHR 18C; 16/05/2018 – Merck’s Keytruda boosts response in hard-to-treat lung cancer; 16/04/2018 – BIOTHERA PHARMACEUTICALS PRESENTS TRANSLATIONAL DATA FROM ONGOING CLINICAL TRIALS SHOWING IMPRIME PGG IN COMBINATION WITH MERCK’S KEYTRUDA® (PEMBROLIZUMAB) DRIVES INNATE AND ADAPTIVE IMMUNE; 03/05/2018 – European Medicines Agency Validates Bristol-Myers Squibb’s Type Il Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC); 25/04/2018 – EC OKS BMY’S OPDIVO FOUR-WEEK DOSING FOR ADVANCED MELANOMA; 06/03/2018 – BRISTOL-MYERS SQUIBB – OPDIVO ALSO WAS APPROVED FOR A SHORTER 30-MINUTE INFUSION ACROSS ALL APPROVED INDICATIONS; 26/04/2018 – Bristol-Myers’ cancer drug Opdivo fuels growth, but revenue falls short

Investors sentiment increased to 1.32 in 2018 Q1. Its up 0.70, from 0.62 in 2017Q4. It improved, as 7 investors sold Infinity Pharmaceuticals, Inc. shares while 12 reduced holdings. 9 funds opened positions while 16 raised stakes. 27.14 million shares or 11.58% more from 24.33 million shares in 2017Q4 were reported. New York-based Goldman Sachs Gp has invested 0% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Deutsche National Bank & Trust Ag owns 124 shares for 0% of their portfolio. Federated Invsts Pa reported 0% stake. Bvf Incorporated Il stated it has 2.08% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Gsa Prtn Llp invested in 0.03% or 302,154 shares. Manufacturers Life Insurance Communications The has 2,628 shares. Dimensional Fund Advisors Limited Partnership owns 734,272 shares for 0% of their portfolio. Baker Bros Advisors Lp reported 0.01% of its portfolio in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Wellington Mngmt Llp reported 0% stake. Qs Investors Ltd Limited Liability Company invested in 158,775 shares or 0% of the stock. Savant Cap Ltd Limited Liability Company has invested 0.01% in Infinity Pharmaceuticals, Inc. (NASDAQ:INFI). Citadel Advisors Ltd Liability Com has 21,511 shares for 0% of their portfolio. Renaissance Technology Lc reported 567,500 shares. Susquehanna International Grp Llp invested in 0% or 244,741 shares. Evercore Wealth Llc reported 118,585 shares stake.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart